Antibody design using LSTM based deep generative model from phage display library for affinity maturation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 03 2021
Historique:
received: 07 08 2020
accepted: 26 02 2021
entrez: 13 3 2021
pubmed: 14 3 2021
medline: 15 12 2021
Statut: epublish

Résumé

Molecular evolution is an important step in the development of therapeutic antibodies. However, the current method of affinity maturation is overly costly and labor-intensive because of the repetitive mutation experiments needed to adequately explore sequence space. Here, we employed a long short term memory network (LSTM)-a widely used deep generative model-based sequence generation and prioritization procedure to efficiently discover antibody sequences with higher affinity. We applied our method to the affinity maturation of antibodies against kynurenine, which is a metabolite related to the niacin synthesis pathway. Kynurenine binding sequences were enriched through phage display panning using a kynurenine-binding oriented human synthetic Fab library. We defined binding antibodies using a sequence repertoire from the NGS data to train the LSTM model. We confirmed that likelihood of generated sequences from a trained LSTM correlated well with binding affinity. The affinity of generated sequences are over 1800-fold higher than that of the parental clone. Moreover, compared to frequency based screening using the same dataset, our machine learning approach generated sequences with greater affinity.

Identifiants

pubmed: 33712669
doi: 10.1038/s41598-021-85274-7
pii: 10.1038/s41598-021-85274-7
pmc: PMC7955064
doi:

Substances chimiques

Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5852

Références

Protein Expr Purif. 2016 Oct;126:1-8
pubmed: 27181246
Nucleic Acids Res. 2015 Jan;43(Database issue):D432-8
pubmed: 25392411
Nucleic Acids Res. 2019 May 21;47(9):e50
pubmed: 30854567
Exp Mol Med. 2017 Mar 24;49(3):e308
pubmed: 28336957
ACS Chem Biol. 2018 Jun 15;13(6):1686-1694
pubmed: 29792670
J Biol Chem. 2015 Sep 4;290(36):21773-86
pubmed: 26088137
Front Immunol. 2018 Mar 01;9:329
pubmed: 29545792
PLoS One. 2019 Feb 11;14(2):e0212048
pubmed: 30742664
Neural Comput. 2000 Oct;12(10):2451-71
pubmed: 11032042
PLoS One. 2015 Jun 05;10(6):e0129125
pubmed: 26046845
Methods. 2013 Mar 15;60(1):99-110
pubmed: 23500657
Nat Biotechnol. 2010 Sep;28(9):965-9
pubmed: 20802495
Curr Opin Biotechnol. 2019 Dec;60:153-158
pubmed: 30849700
Front Immunol. 2018 Oct 16;9:2278
pubmed: 30386328
Cancer Discov. 2020 Aug 25;:
pubmed: 32847940
Bioinformatics. 2018 Dec 1;34(23):4138
pubmed: 29933431
MAbs. 2018 Apr;10(3):431-443
pubmed: 29376776
Nat Methods. 2018 Oct;15(10):816-822
pubmed: 30250057
Sci Rep. 2016 Aug 02;6:30312
pubmed: 27481573
Neural Comput. 1997 Nov 15;9(8):1735-80
pubmed: 9377276
J Mol Biol. 1991 Dec 5;222(3):581-97
pubmed: 1748994
Nat Med. 2015 Jan;21(1):86-91
pubmed: 25501908
Genomics. 2017 Oct;109(5-6):419-431
pubmed: 28669847
Bioinformatics. 2020 Apr 1;36(7):2126-2133
pubmed: 31778140
Front Immunol. 2015 Jan 12;5:673
pubmed: 25628622
MAbs. 2016 Oct;8(7):1177-1194
pubmed: 27416017
Methods. 2013 Mar 15;60(1):38-45
pubmed: 23276752
Comb Chem High Throughput Screen. 2003 Aug;6(5):421-32
pubmed: 12871049
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10753-7
pubmed: 8855252

Auteurs

Koichiro Saka (K)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan.

Taro Kakuzaki (T)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan.

Shoichi Metsugi (S)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan.

Daiki Kashiwagi (D)

Research Division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.

Kenji Yoshida (K)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan.

Manabu Wada (M)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan.

Hiroyuki Tsunoda (H)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan.

Reiji Teramoto (R)

Research Division, Chugai Pharmaceutical Co., Ltd, Kamakura, Kanagawa, Japan. teramoto.reiji11@chugai-pharm.co.jp.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH